Centaurus Financial Inc. Makes New Investment in Moderna, Inc. $MRNA

Centaurus Financial Inc. bought a new stake in Moderna, Inc. (NASDAQ:MRNA) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 4,477 shares of the company’s stock, valued at approximately $314,000.

Other institutional investors also recently made changes to their positions in the company. Allied Private Wealth LLC acquired a new stake in shares of Moderna during the 2nd quarter worth approximately $30,000. Canton Hathaway LLC acquired a new position in Moderna during the 1st quarter valued at approximately $31,000. Frazier Financial Advisors LLC acquired a new position in Moderna during the 2nd quarter valued at approximately $45,000. Freestone Grove Partners LP bought a new position in Moderna during the 2nd quarter worth $46,000. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new stake in Moderna in the second quarter worth $49,000. 75.33% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. William Blair initiated coverage on Moderna in a research note on Friday. They issued an “outperform” rating on the stock. Citigroup increased their price objective on shares of Moderna from $41.00 to $60.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $130.00 price objective on shares of Moderna in a research report on Wednesday, August 19th. Barclays boosted their target price on shares of Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a research note on Monday. Finally, Brookline Capital Markets restated a “buy” rating on shares of Moderna in a research report on Wednesday, August 19th. Seven analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $80.53.

Moderna Trading Down 3.3%

Shares of MRNA stock opened at $137.99 on Friday. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $176.66. The firm has a market capitalization of $55.09 billion, a PE ratio of -17.27 and a beta of 0.91. The stock has a fifty day moving average of $77.11 and a two-hundred day moving average of $59.73. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The company had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. During the same period last year, the company earned ($2.13) earnings per share. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. As a group, research analysts expect that Moderna, Inc. will post -6.11 EPS for the current year.

Insider Transactions at Moderna

In other Moderna news, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the sale, the president directly owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the sale, the insider directly owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. This represents a 4.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 10.80% of the company’s stock.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported that their personalized mRNA melanoma vaccine, intismeran, combined with Keytruda, met the goals of a Phase 3 study involving 1,137 patients. The treatment reduced the risk of melanoma recurrence and distant spread versus Keytruda alone, strengthening the case for Moderna’s oncology pipeline and the commercial potential of the partnership. Reuters cancer vaccine breakthrough article
• Positive Sentiment: The U.S. FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, targeting the XFG subvariant. The approval preserves access to the seasonal COVID-19 vaccine market, though future demand remains an important uncertainty. Reuters FDA approval article
• Positive Sentiment: Argus upgraded Moderna from “Hold” to “Buy” and assigned a $180 price target, indicating additional potential upside based on the company’s oncology opportunity and recent clinical progress. Argus upgrade article
• Neutral Sentiment: Jim Cramer advised a viewer to hold Moderna after the stock’s sharp rally, reflecting continued optimism about the Phase 3 cancer-vaccine result but also caution following the run-up. Jim Cramer Moderna commentary
• Negative Sentiment: Moderna priced an upsized $2.6 billion offering of zero-coupon convertible senior notes due 2032, increased from the initially proposed $2.0 billion. Proceeds may fund oncology investments and debt repayment, but the larger financing raised concerns about future share dilution and explains much of the selling pressure. Moderna convertible notes offering
• Negative Sentiment: BioNTech’s decision to halt a mid-stage personalized mRNA colorectal-cancer vaccine trial after a review weakened sentiment across the mRNA oncology sector, raising broader questions about the difficulty of translating promising technology into successful cancer treatments. BioNTech colorectal cancer trial article

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.